查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2049478

多發性硬化症治療市場報告：按藥物、藥物類型、給藥途徑、分銷管道和地區分類（2026-2034 年）

Multiple Sclerosis Therapies Market Report by Drug, Drug Type, Route of Administration, Distribution Channel, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 137 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球多發性硬化症治療市場規模達289億美元。展望未來，IMARC Group預測，到2034年，市場規模將達到394億美元，2026年至2034年的複合年成長率為3.38%。

多發性硬化症（MS）是一種慢性發炎性免疫介導疾病，可導致脊髓和腦神經細胞去髓鞘化、軸突橫斷和神經退化。常用治療方法包括注射、口服藥物、靜脈輸注、肌肉鬆弛劑、抗憂鬱症和物理治療。注射藥物如干擾素BETA和glatiramer acetate替雷，可經由皮下或肌肉注射給藥。口服藥物包括富馬酸二甲酯、Teriflunomide和Cladribine。靜脈輸注藥物包括Ocrelizumab、那他珠單抗和Alemtuzumab。這些藥物有助於控制症狀、減少復發頻率並調節患者的心率和血壓。

全球復發型多發性硬化症(RRMS)、原發性進展型多發性硬化症 (PPMS)、次發漸進型多發性硬化症 (SPMS) 和漸進復發型緩解型多發性硬化症 (PRMS) 的盛行率不斷上升，是推動市場成長的主要因素。此外，易患這些疾病的老年人口不斷成長，也促進了市場成長。醫療專業人員廣泛使用免疫抑制劑來抑制自體免疫反應，預防多發性硬化症 (MS) 患者的復發。此外，各種技術進步，例如用於有效治療 MS 的創新單株抗體、免疫調節劑、免疫抑制劑和干擾素的開發，也是推動市場成長的主要因素。此外，已開發國家和新興國家的政府正在進行宣傳活動，提高公眾對現有治療方法方案的認知，這為市場創造了積極的前景。其他因素，包括廣泛的研發活動和醫療基礎設施的改善，預計也將進一步推動市場成長。

本報告解答的主要問題

  • 迄今為止，全球多發性硬化症治療市場的發展趨勢是什麼？您預計未來幾年這些趨勢將如何發展？
  • 新冠疫情對全球多發性硬化症治療市場產生了哪些影響？
  • 主要區域市場有哪些？
  • 依藥品種類來看，市場是如何細分的？
  • 按藥品類型分類的市場組成是什麼？
  • 依行政途徑分類的市場區隔如何？
  • 按分銷管道分類的市場區隔如何？
  • 該產業價值鏈包含哪些不同階段？
  • 該行業的主要促進因素和挑戰是什麼？
  • 全球多發性硬化症治療市場的結構是怎麼樣的？主要參與者有哪些？
  • 這個行業的競爭有多激烈？

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：多發性硬化症治療藥物的全球市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依藥物類型分類

  • 免疫調節藥物
    • 主要類型
      • Copaxone
      • Avonex/Pregriddle
      • 吉爾尼亞
      • Tysabri
      • Beta-Ceron/Extavia
      • 特西菲德拉
      • Rebif
      • 安皮拉
  • 免疫抑制劑
    • 主要類型
      • Aubagio
      • 雷姆特拉達
      • Ocrelizumab
      • 津布里塔

第7章 市場區隔：依藥物類型分類

  • 生物製藥
  • 小分子藥物

第8章 市場區隔：依給藥途徑

  • 口服
  • 注射藥物
  • 靜脈

第9章 市場區隔：依分銷通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房

第10章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第11章 SWOT 分析

第12章：價值鏈分析

第13章：波特五力分析

第14章：價格分析

第15章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Abbvie Inc.
    • Bayer Aktiengesellschaft
    • Biogen Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche AG（Roche Holding AG）
    • GlaxoSmithKline Plc
    • Merck & Co. Inc.
    • Novartis AG
    • Sanofi SA
    • Teva Pharmaceutical Industries Ltd.
Product Code: SR112026A2571

The global multiple sclerosis therapies market size reached USD 28.9 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 39.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.38% during 2026-2034.

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.

KEY MARKET SEGMENTATION:

Breakup by Drug:

  • Immunomodulators
    • Copaxone
    • Avonex/Plegridy
    • Gilneya
    • Tysabri
    • Betaseron/Extavia
    • Tecifidera
    • Rebif
    • Ampyra
  • Immunosuppressants
    • Aubagio
    • Lemtrada
    • Ocrelizumab
    • Zinbryta

Breakup by Drug Type:

  • Biologic Drugs
  • Small Molecule Drugs

Breakup by Route of Administration:

  • Oral
  • Injectable
  • Intravenous

Breakup by Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Breakup by Region:

  • North America
    • United States
    • Canada
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Others
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Others
  • Latin America
    • Brazil
    • Mexico
    • Others
  • Middle East and Africa

COMPETITIVE LANDSCAPE:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

KEY QUESTIONS ANSWERED IN THIS REPORT

  • How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug?
  • What is the breakup of the market based on the drug type?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global multiple sclerosis therapies market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Multiple Sclerosis Therapies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug

  • 6.1 Immunomodulators
    • 6.1.1 Market Trends
    • 6.1.2 Major Types
      • 6.1.2.1 Copaxone
      • 6.1.2.2 Avonex/Plegridy
      • 6.1.2.3 Gilneya
      • 6.1.2.4 Tysabri
      • 6.1.2.5 Betaseron/Extavia
      • 6.1.2.6 Tecifidera
      • 6.1.2.7 Rebif
      • 6.1.2.8 Ampyra
    • 6.1.3 Market Forecast
  • 6.2 Immunosuppressants
    • 6.2.1 Market Trends
    • 6.2.2 Major Types
      • 6.2.2.1 Aubagio
      • 6.2.2.2 Lemtrada
      • 6.2.2.3 Ocrelizumab
      • 6.2.2.4 Zinbryta
    • 6.2.3 Market Forecast

7 Market Breakup by Drug Type

  • 7.1 Biologic Drugs
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Small Molecule Drugs
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

  • 8.1 Oral
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Injectable
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Intravenous
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

  • 9.1 Hospital Pharmacies
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Retail Pharmacies
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Online Pharmacies
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbvie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Bayer Aktiengesellschaft
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Biogen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 Bristol-Myers Squibb Company
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 SWOT Analysis
    • 15.3.6 GlaxoSmithKline Plc
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck & Co. Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sanofi S.A.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Multiple Sclerosis Therapies Market: Major Drivers and Challenges
  • Figure 2: Global: Multiple Sclerosis Therapies Market: Sales Value (in Billion USD), 2020-2025
  • Figure 3: Global: Multiple Sclerosis Therapies Market: Breakup by Drug (in %), 2025
  • Figure 4: Global: Multiple Sclerosis Therapies Market: Breakup by Drug Type (in %), 2025
  • Figure 5: Global: Multiple Sclerosis Therapies Market: Breakup by Route of Administration (in %), 2025
  • Figure 6: Global: Multiple Sclerosis Therapies Market: Breakup by Distribution Channel (in %), 2025
  • Figure 7: Global: Multiple Sclerosis Therapies Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Billion USD), 2026-2034
  • Figure 9: Global: Multiple Sclerosis Therapies (Immunomodulators) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 10: Global: Multiple Sclerosis Therapies (Immunomodulators) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 11: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 12: Global: Multiple Sclerosis Therapies (Immunosuppressants) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 13: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 14: Global: Multiple Sclerosis Therapies (Biologic Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 15: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 16: Global: Multiple Sclerosis Therapies (Small Molecule Drugs) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 17: Global: Multiple Sclerosis Therapies (Oral) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 18: Global: Multiple Sclerosis Therapies (Oral) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 19: Global: Multiple Sclerosis Therapies (Injectable) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 20: Global: Multiple Sclerosis Therapies (Injectable) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 21: Global: Multiple Sclerosis Therapies (Intravenous) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 22: Global: Multiple Sclerosis Therapies (Intravenous) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 23: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 24: Global: Multiple Sclerosis Therapies (Hospital Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 25: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 26: Global: Multiple Sclerosis Therapies (Retail Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 27: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 28: Global: Multiple Sclerosis Therapies (Online Pharmacies) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 29: North America: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 30: North America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 31: United States: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 32: United States: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 33: Canada: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 34: Canada: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 35: Asia Pacific: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 36: Asia Pacific: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 37: China: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 38: China: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 39: Japan: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 40: Japan: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 41: India: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 42: India: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 43: South Korea: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 44: South Korea: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 45: Australia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 46: Australia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 47: Indonesia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 48: Indonesia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 49: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 50: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 51: Europe: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 52: Europe: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 53: Germany: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 54: Germany: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 55: France: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 56: France: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 57: United Kingdom: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 58: United Kingdom: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 59: Italy: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 60: Italy: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 61: Spain: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 62: Spain: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 63: Russia: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 64: Russia: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 65: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 66: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 67: Latin America: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 68: Latin America: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 69: Brazil: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 70: Brazil: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 71: Mexico: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 72: Mexico: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 73: Others: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 74: Others: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 75: Middle East and Africa: Multiple Sclerosis Therapies Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 76: Middle East and Africa: Multiple Sclerosis Therapies Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Multiple Sclerosis Therapies Industry: SWOT Analysis
  • Figure 78: Global: Multiple Sclerosis Therapies Industry: Value Chain Analysis
  • Figure 79: Global: Multiple Sclerosis Therapies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Multiple Sclerosis Therapies Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug (in Million USD), 2026-2034
  • Table 3: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Drug Type (in Million USD), 2026-2034
  • Table 4: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Route of Administration (in Million USD), 2026-2034
  • Table 5: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Distribution Channel (in Million USD), 2026-2034
  • Table 6: Global: Multiple Sclerosis Therapies Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 7: Global: Multiple Sclerosis Therapies Market Structure
  • Table 8: Global: Multiple Sclerosis Therapies Market: Key Player